COMPOUNDS CONTAINING BENZO[D][1,3]OXATIOL, BENZO[D][1,3]OXATIOL-3-OXIDE OR BENZO[D][1,3]OXATIOL-3,3-DIOXIDE, AND METHODS/THEIR USE AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 119 Russian patent published in 2023 - IPC C07D411/14 C07D411/12 C07D417/14 A61K31/397 A61K31/454 A61K31/501 A61K31/505 A61K31/53 A61P3/10 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of the formula (B-I) or to its enantiomer, diastereomer or pharmaceutically acceptable salt, where X¹ is SO; X² is O; X³ is selected from a group consisting of CH, CF and N; X⁴, in each case, is independently selected from a group consisting of CH and N; A is selected from a group consisting of and ; R is selected from a group consisting of and ; R¹ is selected from a group consisting of hydrogen, C(O)O-tert-butyl and ; R^2a is hydrogen; R^2b is hydrogen; R³ is selected from a group consisting of CH₂C(O)OR^10a, and ; R⁴ is ; R⁵ is selected from a group consisting of C(O)R⁹, C(O)OR¹⁰, C(O)NR^10aR^10b, and ; R⁶ is ; R^7a is selected from a group consisting of hydrogen and C_1-6-alkyl; R^7b is selected from a group consisting of hydrogen, halogen, C_1-6-alkyl, C_3-7-alkyl with a branched chain, C_1-6-alkoxy; R^7c is selected from a group consisting of hydrogen, halogen and C_1-6-alkyl; R⁸ is C_3-7-alkyl with a branched chain; R⁹ is selected from a group consisting of C_3-7-alkyl with a branched chain and ; R¹⁰ is selected from a group consisting of C_1-6-alkyl and C_3-7-alkyl with a branched chain; R^10a is selected from a group consisting of hydrogen and C_1-6-alkyl; R^10b is selected from a group consisting of hydrogen and C_1-6-alkyl; R^13a, in each case, is independently selected from a group consisting of hydrogen and C_3-7-alkyl with a branched chain; R^13b, in each case, is hydrogen; R^14a, in each case, is independently selected from a group consisting of hydrogen and C(O)O-tret-butyl; R^14b, in each case, is hydrogen; X⁵ is selected from a group consisting of N and CR^7b; n¹ is equal to 1 or 2; n² is equal to 1 or 2, and m is equal to 1. The invention also relates to a pharmaceutical composition acting as an agonist for GPR119 receptor, based on the specified compounds.

EFFECT: new compounds and a pharmaceutical composition based on them are obtained that can be used in medicine for type 2 diabetes mellitus.

36 cl